Clinical Trials on Invasive Pneumococcal Disease (IPD) in Brazil

Total 39 results

Pulmocide Ltd

Recruiting

Safety and Efficacy of PC945 (Opelconazole) in Combination With Other Antifungal Therapy for the Treatment of Refractory Invasive Pulmonary Aspergillosis (OPERA-T Study)

Refractory IPA

Spain, United States, Canada, Italy, Austria, France, Israel, United Kingdom, Belgium, Korea, Republic of, Brazil, Germany, Chile, Greece, Taiwan, Argentina, Colombia
Universidade Federal do Rio de Janeiro

Completed

Negative Beta Glucan in ICU Patients

Candidemia

Brazil
Universidade Federal do Rio de Janeiro
Federal University of São Paulo

Terminated

Validation of an Index of Neutropenia (D-index) in Febrile Neutropenic Cancer Patients (Dindexval)

Invasive Fungal Infections | Invasive Aspergillosis | Invasive Fusariosis

Brazil
Pfizer

Completed

This Is An Open-Label, Non-Comparative Study Designed To Evaluate A Short Course Of IV Anidulafungin, Followed Optionally By Oral Voriconazole, For The Treatment Of Candidemia And Invasive Candidiasis

Candidemia | Invasive Candidiasis

Panama, Brazil, Mexico, Chile, Colombia
University of Sao Paulo
University of Campinas, Brazil

Completed

Intracervical Anesthesia and Pain Associated With Intrauterine Contraceptive Insertion

Anesthesia, Local | Pain, Acute | IUD Insertion Complication

Brazil
AstraZeneca
Hospital Israelita Albert Einstein

Recruiting

Brazilian Reality of Urinary Bladder Cancers - BRA-BLADDER

Urothelial Carcinoma | Muscle-invasive Bladder Cancer | Non Muscle Invasive Bladder Cancer

Brazil
Pfizer

Completed

Study To Assess Pharmacokinetics, Safety & Efficacy of Anidulafungin When Treating Children With Invasive Candidiasis

Candidemia

United States, Taiwan, Spain, United Kingdom, Korea, Republic of, Brazil, Greece, Canada, Italy, Russian Federation
Chiltern Pesquisa Clinica Ltda

Completed

Clinical Trial to Compare the Immunogenicity, Safety, and Tolerability of an Adjuvanted A(H1N1) Influenza Vaccine Versus Non-Adjuvanted A(H1N1) Influenza Vaccines in Patients With Invasive Solid Tumors

H1N1 Influenza Virus | Invasive Solid Tumors

Brazil
Astellas Pharma Inc

Completed

Study of Micafungin in Patients With Invasive Candidiasis or Candidemia

Candidemia | Candidiasis

Belgium, France, Germany, Spain, United States, India, Canada, Brazil, Switzerland, Austria, Croatia, Netherlands, Poland, Czech Republic, United Kingdom
Astellas Pharma Inc
Basilea Pharmaceutica International Ltd

Completed

Isavuconazole (BAL8557) for Primary Treatment of Invasive Aspergillosis

Aspergillosis | Invasive Fungal Infection

Korea, Republic of, Belgium, Australia, United States, Germany, Switzerland, Israel, Canada, Argentina, Chile, Malaysia, Thailand, France, Russian Federation, Hungary, Spain, Brazil, China, India, Egypt, Italy, Turkey, Netherlands, Me... and more
Hospital Sirio-Libanes

Terminated

Prognostic Value Related to the Presence of Thrombosis or Portal Vein Invasion in Patients With Hepatocellular Carcinoma Submitted to Surgery (HSL2012-06)

Hepatocellular Carcinoma | Hepatic Portal Vein Tumor Invasion | Portal Vein Thrombosis

Brazil
Astellas Pharma Inc

Terminated

Micafungin Salvage Mono-therapy in Invasive Aspergillosis

Invasive Aspergillosis

Poland, Belgium, Spain, France, Germany, Colombia, Brazil, Argentina, Hungary, Czech Republic, Croatia, Italy
Federal University of Rio Grande do Sul
Coordenação de Aperfeiçoamento de Pessoal de Nível Superior.; University of...

Completed

Effects of Dance on the Turning Characteristics of Patients With Parkinson's Disease

Parkinson Disease(PD)

Brazil, United Kingdom
Merck Sharp & Dohme LLC

Recruiting

Study of Pembrolizumab (MK-3475) and Pembrolizumab With Other Investigational Agents in Participants With High Risk Non-muscle Invasive Bladder Cancer (MK-3475-057/KEYNOTE-057)

Bladder Cancer

Canada, France, Italy, Netherlands, Turkey, Brazil, Spain, United States, Finland, Puerto Rico, Singapore
F2G Biotech GmbH
Iqvia Pty Ltd; Shionogi

Recruiting

Olorofim Aspergillus Infection Study (OASIS)

Invasive Aspergillosis

United States, Taiwan, Belgium, Spain, Italy, Turkey, New Zealand, China, Canada, Netherlands, Australia, Brazil, Singapore, Israel, France, Thailand, Germany, Japan, Korea, Republic of, United Kingdom
Merck Sharp & Dohme LLC

Completed

A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Children With Sickle Cell Disease (V114-023/PNEU-SICKLE)

Pneumococcal Infections

United States, Brazil, Colombia, Dominican Republic, Greece, Italy, Panama
Merck Sharp & Dohme LLC

Recruiting

Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Bacillus Calmette-Guerin (BCG) in High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC) (MK-3475-676/KEYNOTE-676)

High-risk Non-muscle Invasive Bladder Cancer

Canada, Belgium, United States, Australia, Austria, France, Germany, Greece, Hungary, Italy, Japan, Korea, Republic of, Malaysia, Netherlands, Peru, Poland, Portugal, Spain, Switzerland, Turkey, United Kingdom, China, Brazil, Colombia, ... and more
Janssen Research & Development, LLC

Recruiting

A Study of TAR-200 Versus Intravesical Chemotherapy in Participants With Recurrent High-Risk Non-Muscle-Invasive Bladder Cancer (HR-NMIBC) After Bacillus Calmette-Guérin (BCG) (SunRISe-5)

Non-Muscle Invasive Bladder Neoplasms

Korea, Republic of, United States, United Kingdom, China, Japan, Brazil, Argentina
F2G Biotech GmbH
Iqvia Pty Ltd

Recruiting

Evaluate F901318 Treatment of Invasive Fungal Infections in Patients Lacking Treatment Options (FORMULA-OLS)

Invasive Fungal Infections

United States, Netherlands, Israel, Spain, Korea, Republic of, Belgium, Australia, Germany, France, Brazil, Poland, Egypt, Russian Federation, Thailand, Turkey, United Kingdom, Vietnam
AstraZeneca

Terminated

An Active and Placebo-Controlled Study of Brazikumab in Participants With Moderately to Severely Active Crohn's Disease (INTREPID)

Crohn's Disease | IBD

United States, Italy, Taiwan, Korea, Republic of, Spain, Germany, Poland, Russian Federation, Israel, Ukraine, Canada, Czechia, South Africa, United Kingdom, Hungary, India, Slovakia
Bristol-Myers Squibb

Terminated

A Study Comparing the Efficacy and Safety of Nivolumab in Combination With Bacillus Calmette-Guerin (BCG) Versus BCG Alone in Participants With High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC) (CheckMate 7G8)

Urinary Bladder Neoplasms

United States, Netherlands, Italy, Argentina, Australia, Austria, Brazil, Canada, Chile, France, Germany, Greece, Israel, Japan, Russian Federation, Spain, Sweden
Janssen Research & Development, LLC

Active, not recruiting

A Study of Erdafitinib Versus Investigator Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Guérin (BCG) and Recurred With High Risk Non-Muscle-Invasive Bladder Cancer (NMIBC)

Urinary Bladder Neoplasms

United States, Japan, China, Korea, Republic of, France, Belgium, Czechia, Taiwan, Italy, Poland, United Kingdom, Spain, Germany, Australia, Brazil, Argentina, India
Astellas Pharma Inc
Basilea Pharmaceutica International Ltd

Completed

Isavuconazole in the Treatment of Renally Impaired Aspergillosis and Rare Fungi (VITAL)

Invasive Fungal Infections | Aspergillosis

Korea, Republic of, United States, Belgium, Israel, Mexico, Canada, Brazil, Chile, Argentina, France, Thailand, Egypt, Australia, Germany, India, Lebanon, Poland, Russian Federation, South Africa
Janssen Research & Development, LLC

Recruiting

A Study of TAR-200 in Combination With Cetrelimab or TAR-200 Alone Versus Intravesical Bacillus Calmette-Guérin (BCG) in Participants With BCG-naïve High-risk Non-muscle Invasive Bladder Cancer (HR-NMIBC) (SunRISe-3)

Bladder Cancer

United States, Belgium, Korea, Republic of, Italy, Taiwan, China, United Kingdom, Germany, France, Argentina, Brazil, Poland, Spain, Czechia, Japan, Netherlands, India, Canada, Mexico, Australia, Portugal
Janssen Research & Development, LLC

Completed

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Crohn's Disease | Colitis | Inflammatory Bowel Disease | IBD

United States, France, Poland, United Kingdom, Germany, Spain, Israel, Bulgaria, Serbia, South Africa, Japan, Canada, Australia, Netherlands, Korea, Republic of, Belgium, New Zealand, Brazil, Russian Federation, Austria, Hungary, ... and more
Janssen Research & Development, LLC

Completed

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Crohn's Disease | Colitis | Inflammatory Bowel Disease | IBD

United States, France, Poland, United Kingdom, Germany, Spain, Israel, Bulgaria, Serbia, South Africa, Japan, Australia, Canada, Netherlands, Korea, Republic of, New Zealand, Brazil, Russian Federation, Belgium, Hungary, Croatia, ...
Janssen Research & Development, LLC

Completed

A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)

Crohn's Disease | Colitis | Inflammatory Bowel Disease | IBD

United States, France, Poland, United Kingdom, Germany, Spain, Serbia, South Africa, Japan, Israel, Canada, Australia, Netherlands, Korea, Republic of, Belgium, New Zealand, Brazil, Austria, Ireland, Czech Republic, Hungary, Denmark, Icela...
Daiichi Sankyo, Inc.
AstraZeneca; NSABP Foundation Inc; German Breast Group; Spanish Breast Cancer Research...

Active, not recruiting

A Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in High-risk HER2-positive Participants With Residual Invasive Breast Cancer Following Neoadjuvant Therapy (DESTINY-Breast05)

HER2-Positive Primary Breast Cancer | Residual Invasive Breast Cancer

United States, Spain, France, Germany, Korea, Republic of, United Kingdom, Denmark, Israel, Belgium, Taiwan, Chile, Italy, Japan, Peru, Portugal, China, Turkey, Canada, Ireland, Australia, Greece, Czechia, Singapore, Poland, Romania, Arge... and more
AstraZeneca

Terminated

Placebo-Controlled Study of Brazikumab in Participants With Moderately to Severely Active Ulcerative Colitis (Expedition)

Ulcerative Colitis | IBD

United States, Italy, Taiwan, Korea, Republic of, Germany, Spain, Russian Federation, Japan, South Africa, Hungary, Poland, Israel, Puerto Rico, Czechia, Ukraine, United Kingdom, Canada, India, Slovakia
Bristol-Myers Squibb
Nektar Therapeutics

Completed

A Study of Nivolumab Plus Bempegaldesleukin (Bempeg/NKTR-214) vs Nivolumab Alone vs Standard of Care in Participants With Bladder Cancer That May Have Invaded The Muscle Wall of the Bladder and Who Cannot Get Cisplatin, A Type of Medicine Given To Treat Bladder Cancer

Bladder Cancer | Bladder Tumor | Muscle-Invasive Bladder Cancer

Russian Federation, China, Germany, Italy, United States, Argentina, Australia, Austria, Belgium, Brazil, Canada, Czechia, France, Greece, Israel, Mexico, Netherlands, Poland, Spain, United Kingdom
AstraZeneca

Active, not recruiting

Durvalumab+ Gemcitabine/Cisplatin (Neoadjuvant Treatment) and Durvalumab (Adjuvant Treatment) in Patients With MIBC (NIAGARA)

Muscle Invasive Bladder Cancer

United States, Belgium, France, Germany, Italy, Spain, United Kingdom, Canada, Poland, Taiwan, Vietnam, Turkey, Korea, Republic of, Brazil, Czechia, Japan, Philippines, Israel, Chile, Australia, Netherlands, Russian Federation
Hoffmann-La Roche

Recruiting

A Study of Atezolizumab Versus Placebo as Adjuvant Therapy in Patients With High-Risk Muscle-Invasive Bladder Cancer Who Are ctDNA Positive Following Cystectomy (IMvigor011)

Muscle-invasive Bladder Cancer

Belgium, Korea, Republic of, Japan, Brazil, China, United States, Singapore, France, United Kingdom, Canada, Greece, Italy, Spain, Turkey, Russian Federation, Ukraine, Israel, Czechia, Colombia, Hong Kong, Argentina, Germany, Ireland, Polan... and more
Bristol-Myers Squibb
Ono Pharmaceutical Co. Ltd

Active, not recruiting

A Study to Compare Chemotherapy Alone Versus Chemotherapy Plus Nivolumab or Nivolumab and BMS-986205, Followed by Continued Therapy After Surgery With Nivolumab or Nivolumab and BMS-986205 in Participants With Muscle Invasive Bladder Cancer

Urinary Bladder Neoplasms | Muscle-Invasive Bladder Cancer

Russian Federation, United States, Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, Colombia, Finland, France, Germany, Greece, Israel, Italy, Japan, Korea, Republic of, Mexico, Netherlands, New Zealand, Norway, Portugal, Roman... and more
AstraZeneca

Recruiting

Treatment Combination of Durvalumab, Tremelimumab and Enfortumab Vedotin or Durvalumab and Enfortumab Vedotin in Patients With Muscle Invasive Bladder Cancer Ineligible to Cisplatin or Who Refuse Cisplatin (VOLGA)

Muscle Invasive Bladder Cancer

Netherlands, United Kingdom, Korea, Republic of, Canada, Germany, Italy, Poland, Spain, Turkey, Vietnam, Argentina, Japan, France, Brazil, Taiwan, United States, Israel, Austria, Chile, Colombia, Greece, Hong Kong, Mexico, Portugal, Russian... and more
Novartis Pharmaceuticals

Active, not recruiting

Study of Efficacy and Safety of JDQ443 Single-agent as First-line Treatment for Patients With Locally Advanced or Metastatic KRAS G12C- Mutated Non-small Cell Lung Cancer With a PD-L1 Expression < 1% or a PD-L1 Expression ≥ 1% and an STK11 Co-mutation.

Locally Advanced or Metastatic KRAS G12C-mutated NSCLC With a PD-L1 Expression <1% or a PD-L1 Expression ≥ 1% and an STK11 Co-mutation

Spain, Italy, Austria, Netherlands, United Kingdom, Germany, Thailand, France, Belgium, China, Argentina, Greece, Turkey, Malaysia, Portugal, Hungary, Brazil, United States, India
Astellas Pharma Global Development, Inc.

Completed

A Study of ASP2215 (Gilteritinib), Administered as Maintenance Therapy Following Induction/Consolidation Therapy for Subjects With FMS-like Tyrosine Kinase 3 (FLT3/ITD) Acute Myeloid Leukemia (AML) in First Complete Remission

Acute Myeloid Leukemia (AML) | Acute Myeloid Leukemia With FMS-like Tyrosine Kinase (FLT3) / Internal Tandem Duplication (ITD) Mutation

Taiwan, Poland, Serbia, United States, Brazil, Canada, Czechia, Denmark, France, Germany, Greece, Hungary, Israel, Italy, Japan, Korea, Republic of, Portugal, Romania, Spain, Sweden, United Kingdom
Gilead Sciences
Merck Sharp & Dohme LLC

Recruiting

Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer (ASCENT-04)

Triple Negative Breast Cancer | PD-L1 Positive

United States, Taiwan, Belgium, Australia, Austria, Israel, Spain, Italy, Korea, Republic of, Japan, France, Netherlands, Canada, Turkey, Germany, Malaysia, Singapore, United Kingdom, Hong Kong, Hungary, Mexico, Switzerland, Puerto... and more
Gilead Sciences

Recruiting

Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients With Previously Untreated Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer (ASCENT-03)

Triple Negative Breast Cancer | PD-L1 Negative

United States, Hong Kong, Belgium, Australia, Austria, Israel, Spain, Korea, Republic of, Taiwan, China, Japan, Netherlands, Brazil, Canada, Turkey, France, Germany, Malaysia, United Kingdom, Singapore, Hungary, Mexico, Italy, Switzer... and more
Medtronic

Recruiting

Product Surveillance Registry (PSR)

Coronary Artery Disease | Renal Insufficiency | Neurological Disorders | Intracranial Aneurysm | Surgical Procedures, Operative | Respiratory Therapy | Minimally Invasive Surgical Procedures | Cardiac Rhythm Disorders | Urological Disorders | Cardiovascular Disorders | Digestive Disorders | Mechanical Circulatory... and other conditions

China, France, Italy, United States, Spain, Australia, Belgium, Denmark, Germany, Greece, Hungary, Israel, Japan, Korea, Republic of, Malaysia, Netherlands, Norway, Portugal, Serbia, Sweden, Switzerland, United Kingdom, Argentina, Brazil and more

Clinical Trials on Invasive Pneumococcal Disease (IPD) in Brazil

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Hong Kong

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations